WINNIPEG, MANITOBA--(Marketwire - May 26, 2008) - DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces last patient out in the phase II proof of concept clinical trial of DM-83.
